TMC Life Sciences Bhd, a leading player in the healthcare industry, achieved significant growth in the financial year ending 30 June 2024 (FY2023/24), focusing on enhancing services for women and children to capitalise on the robust growth in FY2024/25, according to a press statement circulated by the company.
Profit before tax increased by 29% to RM52.6 million year-on-year for FY2023/24. In line with this positive performance and in conjunction with Celebrating Life for 30 years, the board of directors has recommended a final single-tier dividend of 0.4898 sen per ordinary share.
During the group's 22nd Annual General Meeting (AGM) today, Chairman Y Bhg Datuk Sri Mohd Mokhtar bin Mohd Shariff highlighted the group's strong financial position, reporting RM188.6 million in cash and bank balances for FY2023/24, a 13% year-on-year increase. .
Acting group CEO, meanwhile, Dr Melvin Heng Jun Li, expressed strong optimism for FY2024/25.
Key highlights from FY2023/24 include the successful partnership between Thomson Hospital Kota Damansara (Thomson) and OncoCare Medical Malaysia Sdn Bhd
This collaboration, established on Sept 5, 2024, enhances the Thomson's oncology offerings, showcasing TMCLS's dedication to advancing cancer care.
Notably, Thomson made history in July 2023 by becoming the first hospital in Southeast Asia to administer the US-approved Spinraza for Spinal Muscular Atrophy. Additionally, the hospital also performed its first bowel atresia surgery on a premature infant in April 2024,
demonstrating a commitment to pioneering medical procedures.
Looking ahead, TMC Life is strategically poised to capitalise on growth opportunities in the region, driven by increased capacity at Thomson and a resurgence in the fertility business through TMC Fertility. Additionally, a promising uptick in medical tourism further
enhances the group's potential for success.
TMC Life is also committed to addressing climate change, with initiatives designed to achieve Net Zero by 2050. The group's dedication to sustainable practices aligns with its ongoing efforts to expand its footprint in the healthcare sector.
